On Demand Partnerships Position 3DBio to partner with hospitals, transplant centers and contract development/manufacturing organizations to pilot on-demand engineered tissues and explore licensing of the bioprinting platform for rapid regenerative solutions.

Credible Leadership Board appointments of Sol Barer and Kevin Slawin bolster credibility with investors and potential collaborators, enabling faster engagement with pharma, academia, and grant programs for strategic partnerships.

Clinical Stage Revenue With zero to modest current revenue, pursue early income through CDMO services, joint development agreements, and licensing of bioprinting materials and processes to other biotech players seeking prototyping and personalized tissue capabilities.

Geography and Compliance Leverage New York base and a compact team to target East Coast healthcare systems and US regulatory pathways, framing ISO readiness and regulatory credibility to accelerate pilot programs and collaborations.

Tech and Materials Ecosystem Capitalize on the integrated 3D-bioprinting and materials tech stack by aligning with biomaterial suppliers and data-enabled collaboration partners, offering end-to-end solutions including data management for tissue outcomes.